Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses

Rivers, J.K.

Skin Therapy Letter 9(1): 1-3

2004


ISSN/ISBN: 1201-5989
PMID: 14716439
Document Number: 583288
Actinic Keratoses (AKs) are epidermal skin lesions that have the potential to develop into squamous cell carcinoma. Many of the treatment options available can cause discomfort, pain or skin irritation. Topical 3% diclofenac in 2.5% hyaluronan gel (Solaraze, Bioglan Pharma) is a relatively new treatment that has been shown to be effective and well tolerated for the treatment of AKs.

Document emailed within 1 workday
Secure & encrypted payments